As stated in Methods, all patients with available tumor tissue sample were screened for mutations in the entire series of additional candidate genes (KRAS, ALK, BRAF, MET) regardless of the positive or negative result of the EGFR mutation testing. The gene discussed is BRAF; the disease is neoplasm.